Highlights
IIA supported (ever)1 patentProfile claimed by owner
About
Immunomodulatory Treatment for Autoimmune Diseases
TPCera develops a new type of immunomodulatory compound that shifts the immune system from an inflammatory state into an anti-inflammatory one. The company is focused on shifting macrophages from M1 to M2, which has the potential to modulate autoimmune diseases. TPCera's lead compound is TPC1022. Its subcutaneous and oral administrations have produced promising results in preclinical studies on three autoimmune mice models: lupus, colitis, and rheumatoid arthritis.
Identity
| Name | TPCera |
|---|---|
| Slug | tpcera |
| Type / kind | startup |
| Crunchbase ID | tpcera |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPqq2pgJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Oct 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Professor Racah Street 1, Jerusalem, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesBiotechnologyPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsimmunologycrohn-s-diseasebiopharmaceuticalpharma-companiesdrug-discoveryautoimmune-diseases
Funding
| Total raised | $4.4M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}